Sulfonamides for the prevention of diabetes
The use of sulfonamides of formula (I) wherein R and R 1 are as defined in the description, for the preparation of medicaments for the prevention of diabetes, in particular of type-1 diabetes is herein disclosed.
1. A method of protecting pancreatic beta-cells from structural and/or functional injury to a patient in need thereof, the method comprising:
identifying an individual at risk for Type 1 diabetes through obtaining a physical sample of a patient in need thereof;
and
administering to the patient a medicament comprising a compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein R 1 is (C 1 -C 6 ) alkyl and R is selected from the group consisting of linear or branched 4-(C 1 -C 6 ) alkyl, 4-trifluoromethane-sulfonyloxy, and 3-benzoyl.
2. The method of claim 1 , wherein the medicament delays the onset and/or reduces the progression of Type 1 diabetes in the individual.
3. The method of claim 1 , wherein the medicament reduces the severity of Type 1 diabetes following onset of diabetes in the individual.
4. The method of claim 1 , wherein the medicament prevents the onset of Type 1 diabetes in the individual.
5. The method of claim 1 , wherein the compound of formula I is selected from the group consisting of R(−)-N-2-[(4-isobutylphenyl)propionyl]-methanesulfonamide and R(−)-2-[(4′-trifluoromethanesulfonyloxy)phenyl]propionyl-methanesulfonamide.
6. The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of lysine salts and sodium salts.
7. A method of delaying the onset and/or reducing the progression of diabetes in an individual, the method comprising:
identifying an individual at risk for Type 1 diabetes; and
administering to the individual a medicament comprising a compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein R is selected from linear or branched 4-(C 1 -C 6 ) alkyl, 4-trifluoromethane-sulfonyloxy, and 3-benzoyl and R 1 is (C 1 -C 6 ) alkyl.
8. The method of claim 7 , wherein the medicament reduces the severity of Type 1 diabetes following onset of diabetes in the individual.
9. The method of claim 7 , wherein the medicament prevents the onset of Type 1 diabetes in the individual.
10. The method of claim 7 , wherein the compound of formula I is selected from the group consisting of R(−)-N-2-[(4-isobutylphenyl)propionyl]-methanesulfonamide and R(−)-2-[(4′-trifluoromethanesulfonyloxy)phenyl]propionyl-methanesulfonamide.
11. The method of claim 7 , wherein the pharmaceutically acceptable salt is selected from the group consisting of lysine salts and sodium salts.
12. A method of inhibiting a diabetes-related rise in glycemic levels of an individual, the method comprising:
identifying an individual at risk for Type 1 diabetes; and
administering to the individual a medicament comprising a compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein R is selected from linear or branched 4-(C 1 -C 6 ) alkyl, 4-trifluoromethane-sulfonyloxy, and 3-benzoyl and R 1 is (C 1 -C 6 ) alkyl.
13. The method of claim 12 , wherein the medicament delays the onset and/or the progression of Type 1 diabetes in the individual.
14. The method of claim 12 , wherein the medicament reduces the severity of Type 1 diabetes following onset of Type 1 diabetes in the individual.
15. The method of claim 12 , wherein the medicament prevents the onset of Type 1 diabetes in the individual.
16. The method of claim 12 , wherein the compound of formula I is selected from the group consisting of R(−)-N-2-[(4-isobutylphenyl)propionyl]-methanesulfonamide and R(−)-2-[(4′-trifluoromethanesulfonyloxy)phenyl]propionyl-methanesulfonamide.
17. The method of claim 12 , wherein the pharmaceutically acceptable salt is selected from the group consisting of lysine salts and sodium salts.